We aimed to identify specific metabolomic changes and biomarkers for the differential clinical diagnosis of different subtypes of moyamoya disease (MMD). We conducted an pseudotargeted metabolomics analysis and pseudotargeted metabolomics analysis revealed decreased LPC expression in patients wit...